日本厚生劳动省的一个专家小组已批准将住友制药的Amchepry纳入国家医疗保险覆盖范围，这是一种源自iPS细胞的帕金森病治疗药物。此举使其成为全球首个商业化的iPS细胞医疗产品。
该项批准来自日本厚生劳动省下属的一个专家小组，涵盖了住友制药用于治疗帕金森病的Amchepry。
Amchepry由诱导多能干细胞制成。这一决定确立了该产品作为全球首个实现商业化的此类疗法的地位。
该专家小组的行动为患者通过日本国家医疗保健系统获得更广泛的治疗扫清了障碍。
Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.
由 AI 报道
Researchers in Australia have found that a mysterious FDA-approved drug, called compound X, removes toxic alpha-synuclein proteins from the brains of mice with Parkinson's-like symptoms. The treatment improved the animals' balance and mobility by enhancing the brain's glymphatic waste disposal system. The findings were presented at a symposium in the UK.
PhilHealth has expanded its Z Benefits Package to cover at least 10 rare genetic conditions. The benefits include case rates ranging from roughly P99,000 to P739,000. This move supports ongoing efforts to improve care for rare disease patients in the Philippines.
由 AI 报道
Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.